A new study funded by the National Institutes of Health has raised a question that could reshape the future of obesity and addiction treatment: what if popular weight-loss medicines are not just reducing hunger, but also silencing the brain’s craving system itself?

Researchers at the University of Virginia have found that a newer generation of oral GLP-1 drugs appears to reduce “pleasure eating” — the urge to eat for comfort, reward, or emotional satisfaction rather than genuine hunger. Their findings, published with support from the National Institute on Drug Abuse, suggest these medicines may influence some of the deepest reward circuits in the brain.

The discovery comes at a time when drugs such as semaglutide and newer oral compounds are rapidly gaining popularity worldwide. Millions are already using them for obesity and diabetes. But scientists say the full picture of how these medicines work inside the brain is only beginning to emerge.

Unlike earlier injectable GLP-1 medicines, the researchers focused on small-molecule oral drugs, including orforglipron and danuglipron. These pills are cheaper to manufacture and easier to take, making them particularly important for wider public access.

“To understand the effects we’re seeing in patients, we need to understand the neural mechanisms behind them,” said Lorenzo Leggio, adding that the rising accessibility of these medicines makes such research urgent.

For years, scientists believed GLP-1 drugs mainly acted on areas of the brain linked to survival and energy balance. Earlier work had shown that they reduce hunger by influencing the hypothalamus and hindbrain — regions that help regulate appetite and fullness.

But this latest study uncovered something far more intriguing.

Inside a Virginia laboratory, researchers genetically modified mice so their GLP-1 receptors, which are proteins that help regulate appetite, behaved more like those found in humans. After months of closely tracking neural activity, the team noticed something unexpected under advanced brain-mapping techniques. The drugs were activating the central amygdala—a deeper brain structure strongly linked to desire, emotional reward, and compulsive behaviour.

That finding surprised many researchers because scientists previously believed these medicines could not directly reach such deep reward-processing centres.

The central amygdala plays a powerful role in what experts call “hedonic feeding”. In simple terms, this means eating because food feels pleasurable, comforting, or emotionally satisfying — not because the body genuinely needs energy. It is the same reward system often linked to cravings for alcohol, nicotine, or other addictive substances.

Further experiments showed the drugs reduced dopamine release in the brain’s reward hubs during pleasure-driven eating. Dopamine is often described as the brain’s “feel-good chemical”. It helps create motivation, excitement, and craving. Lower dopamine activity may explain why some people taking GLP-1 drugs report reduced interest not only in food but occasionally in alcohol or compulsive behaviours as well.

“We’ve known that GLP-1 drugs suppress feeding behaviour driven by energy demand,” said Ali Guler. “Now it seems oral small-molecule GLP-1s also dial back eating for pleasure by engaging a brain reward circuit.”

Scientists caution that the findings are still early and based on animal research. Human studies will be needed before doctors can draw firm conclusions. Yet addiction researchers are watching closely.

Several ongoing studies globally are already examining whether GLP-1 medicines could help reduce cravings linked to alcohol dependence, smoking, and substance use disorders. If proven effective, experts believe these medicines could potentially pave the way for a completely new approach to brain-based treatment for compulsive behaviour.

For ordinary people struggling with emotional eating, binge cravings, or addiction, the findings may also explain why some patients describe an unusual sense of “mental quietness” after starting these drugs.

What began as a treatment for blood sugar and obesity may now be revealing something far bigger — the possibility of calming the brain’s reward engine itself.